# To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers

> **NCT04150172** · PHASE1 · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Rebamipide SR 150mg
- **DRUG:** Rebamipide IR 100mg

## Key facts

- **NCT ID:** NCT04150172
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-22
- **Primary completion:** 2019-05-01
- **Final completion:** 2019-05-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150172, "To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT04150172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*